AIMS: Recent clinical and experimental evidences demonstrate an association between augmented circulating lipocalin-2 [a pro-inflammatory adipokine] and cardiac dysfunction. However, little is known about the pathophysi-ological role of lipocalin-2 in heart. The present study was designed to compare the heart functions of mice with normal (WT) or deficient lipocalin-2 (Lcn2-KO) expression. METHODS AND RESULTS: Echocardiographic analysis revealed that the myocardial contractile function was significantly improved in hearts of Lcn2-KO mice, under both standard chow and high fat diet conditions. The heart function before and after I/R injury (20-min of global ischemia followed by 60-min of reperfusion) was assessed using the Langendorff perfusion system. Compared to WT littermates, hearts from Lcn2-KO mice showed improved functional recovery and reduced infarct size following I/R. Under baseline condition, the mitochondrial function of Lcn2-KO hearts was significantly enhanced, as demonstrated by biochemical analysis of respiratory chain activity and markers of biogenesis, as well as electron microscopic investigation of the mitochondrial ultrastructure. Acute or chronic administration of lipocalin-2 impaired cardiac functional recovery to I/R and dampened the mitochondrial function in hearts of Lcn2-KO mice. These effects were associated with an extensive modification of the fatty acyl chain compositions of intracellular phospholipids. For example, lipocalin-2 facilitated the redistribution of linoleic acid (C18:2) among different types of phospholipids, including cardiolipin, a structurally unique phospholipid located mainly on the inner membrane of mitochondria. CONCLUSIONS: Lack of lipocalin-2 improved the functional recovery of isolated mice hearts subjected to I/R, which is associated with restoration of mitochondrial function and phospholipids remodeling.
AIMS: Recent clinical and experimental evidences demonstrate an association between augmented circulating lipocalin-2 [a pro-inflammatory adipokine] and cardiac dysfunction. However, little is known about the pathophysi-ological role of lipocalin-2 in heart. The present study was designed to compare the heart functions of mice with normal (WT) or deficient lipocalin-2 (Lcn2-KO) expression. METHODS AND RESULTS: Echocardiographic analysis revealed that the myocardial contractile function was significantly improved in hearts of Lcn2-KO mice, under both standard chow and high fat diet conditions. The heart function before and after I/R injury (20-min of global ischemia followed by 60-min of reperfusion) was assessed using the Langendorff perfusion system. Compared to WT littermates, hearts from Lcn2-KO mice showed improved functional recovery and reduced infarct size following I/R. Under baseline condition, the mitochondrial function of Lcn2-KO hearts was significantly enhanced, as demonstrated by biochemical analysis of respiratory chain activity and markers of biogenesis, as well as electron microscopic investigation of the mitochondrial ultrastructure. Acute or chronic administration of lipocalin-2impaired cardiac functional recovery to I/R and dampened the mitochondrial function in hearts of Lcn2-KO mice. These effects were associated with an extensive modification of the fatty acyl chain compositions of intracellular phospholipids. For example, lipocalin-2 facilitated the redistribution of linoleic acid (C18:2) among different types of phospholipids, including cardiolipin, a structurally unique phospholipid located mainly on the inner membrane of mitochondria. CONCLUSIONS: Lack of lipocalin-2 improved the functional recovery of isolated mice hearts subjected to I/R, which is associated with restoration of mitochondrial function and phospholipids remodeling.
Authors: Irina Kratchmarova; Dario E Kalume; Blagoy Blagoev; Philipp E Scherer; Alexandre V Podtelejnikov; Henrik Molina; Perry E Bickel; Jens S Andersen; Minerva M Fernandez; Jacob Bunkenborg; Peter Roepstorff; Karsten Kristiansen; Harvey F Lodish; Matthias Mann; Akhilesh Pandey Journal: Mol Cell Proteomics Date: 2002-03 Impact factor: 5.911
Authors: Mingyan Zhou; Aimin Xu; Paul K H Tam; Karen S L Lam; Lawrence Chan; Ruby L C Hoo; Jing Liu; Kim H M Chow; Yu Wang Journal: Hepatology Date: 2008-10 Impact factor: 17.425
Authors: Genevieve C Sparagna; Chris A Johnson; Sylvia A McCune; Russell L Moore; Robert C Murphy Journal: J Lipid Res Date: 2005-03-16 Impact factor: 5.922
Authors: Xianlin Han; Jingyue Yang; Kui Yang; Zhongdan Zhao; Dana R Abendschein; Richard W Gross Journal: Biochemistry Date: 2007-05-08 Impact factor: 3.162
Authors: Zheqing Cai; Hua Zhong; Marta Bosch-Marce; Karen Fox-Talbot; Lei Wang; Chiming Wei; Michael A Trush; Gregg L Semenza Journal: Cardiovasc Res Date: 2007-10-11 Impact factor: 10.787
Authors: Kevin J Ashton; Melissa E Reichelt; S Jamal Mustafa; Bunyen Teng; Catherine Ledent; Lea M D Delbridge; Polly A Hofmann; R Ray Morrison; John P Headrick Journal: Purinergic Signal Date: 2016-09-30 Impact factor: 3.765
Authors: Erfei Song; Sofhia V Ramos; Xiaojing Huang; Ying Liu; Amy Botta; Hye Kyoung Sung; Patrick C Turnbull; Michael B Wheeler; Thorsten Berger; Derek J Wilson; Christopher G R Perry; Tak W Mak; Gary Sweeney Journal: Proc Natl Acad Sci U S A Date: 2018-01-29 Impact factor: 11.205
Authors: Sul A Lee; Sanjeev Noel; Johanna T Kurzhagen; Mohanraj Sadasivam; Phillip M Pierorazio; Lois J Arend; Abdel R Hamad; Hamid Rabb Journal: J Immunol Date: 2019-12-30 Impact factor: 5.422
Authors: Erfei Song; James Ws Jahng; Lisa P Chong; Hye K Sung; Meng Han; Cuiting Luo; Donghai Wu; Stellar Boo; Boris Hinz; Matthew A Cooper; Avril Ab Robertson; Thorsten Berger; Tak W Mak; Isaac George; P Christian Schulze; Yu Wang; Aimin Xu; Gary Sweeney Journal: Am J Transl Res Date: 2017-06-15 Impact factor: 4.060